Search Results
Nov 07, 2025, 17:14 ET Boehringer awarded FDA Commissioner's National Priority Voucher for HERNEXEOS® in HER2 lung cancer
need for additional treatment options for people living with advanced NSCLC. Up to 4% of lung cancers are driven by HER2 (ERBB2) mutations (or gene alterations).9 Mutations in HER2 (ERBB2) can lead to overexpression and overactivation, which can in turn result in uncontrolled cell
More news about: Boehringer Ingelheim
Nov 07, 2025, 16:07 ET Conheça os procedimentos que são eficazes para melhorar o rosto flácido após perda de peso induzida por medicamentos
2019. 45; 718-24 9. Waibel J, et al. A randomized, comparative study describing the gene signatures of poly-l-lactic acid (PLLA-SCA) and calcium hydroxylapatite (CaHA) in the treatment of nasolabial folds. Poster presented at the IMCAS World
More news about: Galderma
Nov 07, 2025, 11:30 ET Akeso Unveils Promising Preclinical Data for IL-1RAP Targeting Antibody (AK135) at SITC 2025
high affinity for IL-1RAP, with binding activity comparable to or superior to that of the control antibody CAN04. Reporter gene assays further confirmed that AK135 effectively inhibits the activation of IL-1, IL-33, and IL-36 signaling pathways, showing excellent half-maximal
More news about: Akeso, Inc.
Nov 07, 2025, 10:30 ET Preimplantation Genetic Testing Market worth $1,135.0 million by 2030 with 10.5% CAGR | MarketsandMarkets™
maintain its dominance during the forecast period. The market's growth is driven by the increasing adoption of NGS for comprehensive chromosomal and single-gene disorder screening in embryos prior to implantation. By enabling high-throughput analysis and precise detection of genetic abnormalities,
More news about: MarketsandMarkets
Nov 07, 2025, 10:03 ET Klotho Neurosciences Wins the 2025 BioTech Breakthrough 'Cell Therapy Innovation of the Year' Award
Klotho Neurosciences earned this recognition for its pioneering work developing transformative gene and cell therapies using a patented, secreted form of the human Klotho gene (s-KL) to address devastating neurodegenerative and age-related diseases, including ALS, Alzheimer's disease,
More news about: Klotho Neurosciences, Inc.
Nov 07, 2025, 08:58 ET Resonant Wins BioTech Breakthrough Awards' "DNA Sequencing Innovation Of The Year"
Parkinson's, ALS, and related diseases." The BioTech Breakthrough Awards celebrate excellence and innovation across biotechnology, from gene and cell therapies to advanced diagnostics and sustainable biomanufacturing. This year's program received thousands of nominations from more than 15
More news about: Resonant
Nov 07, 2025, 08:00 ET Shinobi Therapeutics Announces the Appointment of Dr. Laurent Fischer as Chair of its Board of Directors
billion sale to SOBI and most recently, the sale of Adverum Biotechnologies to Eli Lilly in October 2025, handing off an advanced and potentially curative gene therapy for wet AMD. Dr. Fischer brings extensive board experience, including current positions as first independent Director
More news about: Shinobi Therapeutics
Nov 07, 2025, 07:50 ET Alonzo Mourning Shares His Journey to Raise Awareness for Kidney Disease
powerful message of perseverance. Mourning was diagnosed with focal segmental glomerulosclerosis — a rare kidney condition caused by variants in the APOL1 gene — shortly after winning a gold medal with Team USA at the 2000 Olympics. "I had just won the gold medal with Team USA in the
More news about: Mediaplanet
Nov 07, 2025, 06:12 ET October in Review: 10 Top Health Press Releases
Biotechnologies This acquisition aligns Lilly's genetic medicine capabilities with opportunity to expand gene therapy's potential to alleviate the burden of age-related diseases.
More news about: PR Newswire
Nov 07, 2025, 06:02 ET 12 Top Press Releases from October
Lilly to Acquire Adverum Biotechnologies Adverum's lead program, Ixo-vec, is a Phase 3 gene therapy designed to treat vision loss associated with wet age-related macular degeneration with a single intravitreal dose.
More news about: PR Newswire
Nov 06, 2025, 21:00 ET Argo Biopharma to Present Positive Phase I Results of siRNA Therapeutic BW-20805 for HAE at ACAAI 2025
treatments require frequent dosing, highlighting the need for long-acting, preventive therapies. BW-20805 targets human hepatic PKK mRNA to inhibit PKK gene expression, offering the potential for effective prevention of HAE attacks with a significant and longer-lasting therapeutic effect.
More news about: Argo Biopharmaceutical Co., Ltd
Nov 06, 2025, 16:03 ET BioLife Solutions Reports Third Quarter 2025 Financial Results
Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of cell processing tools and services for the cell and gene therapy ("CGT") market, announces financial results for the three and nine months ended September 30, 2025.
More news about: BioLife Solutions, Inc.
Nov 06, 2025, 14:02 ET MyOme Launches Proactive Health Network — A First-of-Its-Kind National Platform for Concierge & Executive Health Clinics Powered by Whole-Genome Precision
understand and act on their genetic risks. Using whole-genome sequencing and advanced analytics, MyOme delivers actionable reports that integrate single-gene variants, pharmacogenomic data, and polygenic risk scores to guide prevention, treatment, and long-term health planning.Learn more at
More news about: MyOme, Inc
Nov 06, 2025, 11:36 ET Cloned Meat Enters the Canadian Food Supply Without Labeling or Review
Canadian food. The company also invites its retail and supply chain partners to join in advancing transparency around animal cloning and gene-edited production, helping make responsibly raised pork accessible to everyone. About duBreton
More news about: duBreton
Nov 06, 2025, 10:45 ET Pharmacovigilance Market to Reach $26.2 billion, Globally, by 2034 at 12.3% CAGR: Allied Market Research
patient safety by global regulatory authorities. As pharmaceutical and biotechnology companies expand their pipelines to include biologics, biosimilars, gene therapies, and personalized medicines, the need for continuous safety surveillance throughout the product lifecycle has intensified. Regulatory mandates
More news about: Allied Market Research
Nov 06, 2025, 10:04 ET Children's adventure book kickoff raises $5,000 for rural food shelf through Spin Speed Books
Gene Walden is a best-selling author of about 30 books (mostly non-fiction), and a former contributor to a number of prominent publications, such as The Wall Street Journal, Investor's Business Daily, Money, and Consumer Digest. A graduate of Indiana University, Gene makes his home
More news about: Spin Speed Books
Nov 06, 2025, 09:30 ET Vector BioMed Expands LENTIVERSE™ Platform and Unveils New Brand Identity to Close the Gap Between CGT Innovation and Patient Access
platform alongside the unveiling of its new brand identity, designed to accelerate global gene therapy access by providing custom and ready-to-deploy solutions. This expansion strengthens the company's mission to make gene therapies more accessible and cost-effective for patients worldwide.
More news about: Vector BioMed
Nov 06, 2025, 09:30 ET Biohub Launches First Large-Scale Scientific Initiative Combining Frontier AI with Frontier Biology to Cure or Prevent Disease
frontier medicine. AI could enable advances like early disease detection, monitoring, and prevention; programmable cellular medicines; personalized, gene-editing-based cures; and approaches to prevent and cure inflammatory and chronic disease. Early Milestones:
More news about: Biohub
Nov 06, 2025, 08:35 ET Tenthpin Expands footprint in India
Sciences clients around the world. With deep expertise in SAP Batch Release Hub (BRH), SAP Intelligent Clinical Supply Management (ICSM), and SAP Cell and Gene Treatment Orchestration (CGTO), and our own AI-powered, GxP-ready Tenthpin software solutions, this center will strengthen our ability to accelerate
More news about: Tenthpin
Nov 06, 2025, 08:00 ET Cure by Deerfield Middle East Health Accelerator Selects 15 Startups for Inaugural Cohort
that brings single-visit detection into the neighborhood clinic. Pinecone Therapeutics (USA): Gene therapy program targeting propionic acidemia (PA), a rare metabolic disorder. Valeo Health (UAE):
More news about: Cure
Nov 06, 2025, 08:00 ET Edgewise Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
and function in six- to 14-year-old participants with Duchenne who have been previously treated with gene therapy. FOX participants are on average over 10 years old and four years out from receiving gene therapy. Initial results from the FOX study support that sevasemten 10 mg has the potential to reduce
More news about: Edgewise Therapeutics
Nov 06, 2025, 07:27 ET MavriX Bio Announces First Patient Dosed in ASCEND-AS Trial of MVX-220, Investigational Gene Therapy for Angelman Syndrome
(NCT07181837) represents the first clinical evaluation of a gene therapy for AS. Supported by the Foundation for Angelman Syndrome Therapeutics (FAST) and AS2Bio, MavriX Bio developed MVX-220 to restore functional expression of the UBE3A gene in neurons using targeted AAV delivery to the central
More news about: AS2Bio
Nov 06, 2025, 07:05 ET REGENXBIO Reports Third Quarter 2025 Financial Results and Operational Highlights
lanparvovec (RGX-121) on track to be first gene therapy and one-time treatment for MPS II; PDUFA date February 8, 2026 Surabgene lomparvovec (sura-vec, ABBV-RGX-314) on track to be first gene therapy for chronic retinal disease
More news about: REGENXBIO Inc.
Nov 06, 2025, 07:00 ET SkylineDx Wins 2025 BioTech Breakthrough Award for "Diagnostics Company of the Year"
decisions across all stages of melanoma and is available commercially in the U.S. and Europe. The Merlin GP-GEP Test combines clinicopathologic factors with gene expression analysis to assess a patient's risk of melanoma metastases. SkylineDx recently published a landmark study in
More news about: SkylineDx
Nov 06, 2025, 05:04 ET Proxima Clinical Research Acquired, Names Industry Veteran Eric Ross as new CEO to Drive Growth in Houston MedTech Hub
MedTech right here in Texas." Howell's ownership also extends to HGI Clinical, a CRO dedicated to early-phase oncology and cell and gene therapy drug development. This synergy between Proxima and HGI Clinical is expected to create a robust platform for accelerated medical advancements.
More news about: ProximaCRO